tirzepatide por cuanto tiempo se toma Tirzepatida: ¿Qué es y qué debes ser cauteloso? La tirzepatida, un nuevo medicamento para diabetes tipo 2, está llegando a México y promete ser una solución para la pérdida de peso Semaglutida y Tirzepatida: Todo lo

Health coaches and nurses are valuable, but they should not be prescribing a weight loss drug independently

Longitudinal analyses from the Phase 2 and Phase 3 trials show that the incidence of new-onset nausea and vomiting peaked during the first 4-8 weeks of treatment and then declined substantially during the maintenance phase

Asia-Pacific is expected to be the fastest growing region in the GLP-1 receptor agonists obesity drugs market during the forecast period due to increasing obesity rates, rising healthcare awareness, and expanding access to advanced diabetes and obesity care Long-acting GLP-1 Receptor Agonists segment dominated the GLP-1 receptor agonists obesity drugs market with a market share of 55.5% in 2024, driven by its superior weight loss efficacy, once-weekly dosing convenience, and broad adoption of drugs such as semaglutide and tirzepatide Report Scope and GLP-1 Receptor Agonists Obesity Drugs Market Segmentation GLP-1 Receptor Agonists Obesity Drugs Market Trends Expansion Beyond Diabetes Through Multi-Indication Approvals A significant and accelerating trend in the global GLP-1 receptor agonists obesity drugs market is the expansion of these therapies beyond type 2 diabetes into broader indications such as chronic obesity, cardiovascular risk reduction, and potentially even conditions such as sleep apnea and nonalcoholic steatohepatitis (NASH)

Presented for research literature review only Iqbal J et al